DAL
62
-2
UPS
45
-3
JPM
60
-2
F
42
3
CMCSA
50
-2
PNR
69
-2
QCOM
51
-5
ITW
62
-2
SCHW
36
-4
MCK
48
3
TSN
35
3
AIG
42
-2
FTI
58
7
KO
49
2
LMT
64
2
TXN
43
-5
C
58
-2
SLB
50
2
RIG
47
4
PNW
73
4
DAL
62
-2
UPS
45
-3
JPM
60
-2
F
42
3
CMCSA
50
-2
PNR
69
-2
QCOM
51
-5
ITW
62
-2
SCHW
36
-4
MCK
48
3
TSN
35
3
AIG
42
-2
FTI
58
7
KO
49
2
LMT
64
2
TXN
43
-5
C
58
-2
SLB
50
2
RIG
47
4
PNW
73
4
Financhill
Back

Biomarin Pharmaceutical Quote, Financials, Valuation and Earnings

Invest in the Next Big AI Disruptor Today

Learn More
Sell
32

BMRN
Biomarin Pharmaceutical

Last Price:
70.07
Seasonality Move:
6.37%

7 Day Trial

ALL ACCESS PASS

$ 7

Supercharge Your Portfolio with This High-Traction AI Startup

Learn More

Biomarin Pharmaceutical Price Quote

$70.07
-0.03 (-0.3%)
(Updated: October 2, 2024 at 6:10 AM ET)

Biomarin Pharmaceutical Key Stats

Sell
32
Biomarin Pharmaceutical (BMRN) is a Sell
Day range:
$69.81 - $70.74
52-week range:
$67.75 - $99.56
Dividend yield:
0%
P/E ratio:
80.57
P/S ratio:
5.28
P/B ratio:
2.52%
Volume:
1M
Avg. volume:
2.2M
1-year change:
-20.77%
Market cap:
$13.3B
Revenue:
$2.4B
EPS:
$1.33

How Much Does Biomarin Pharmaceutical Make?

Is Biomarin Pharmaceutical Growing As A Company?

Biomarin Pharmaceutical Stock Price Performance

What Is Biomarin Pharmaceutical 52-Week High & Low?

Biomarin Pharmaceutical Price To Free Cash Flow

Is It Risky To Buy Biomarin Pharmaceutical?

Is Biomarin Pharmaceutical Cash Flow Positive?

  • What Is BMRN Cash Flow From Operations?
    Cash flow from operations (TTM) is $328.9M
  • What Is Biomarin Pharmaceutical’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$20.1M
  • What Is Biomarin Pharmaceutical’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$34.5M

Biomarin Pharmaceutical Return On Invested Capital

  • Is Management Doing A Good Job?
    BMRN return on invested capital is 4.22%
  • What Is Biomarin Pharmaceutical Return On Assets?
    ROA measures how assets are converting to revenues and is 3.76%
  • What Is BMRN Return On Equity?
    ROE is a measure of profitability and is 5.13%

Biomarin Pharmaceutical Earnings Date & Stock Price

Biomarin Pharmaceutical Competitors

Biomarin Pharmaceutical Dividend Yield

Biomarin Pharmaceutical Analyst Estimates

YoY Growth Past Surprise
EPS: 89.66% 60.99%
Revenue: 19.61% 7.23%

Analyst Recommendations

Buy Recommendations: 14
Hold Recommendations: 6
Sell Recommendations: 0
Price Target: 104.74
Upside from Last Price: 49.41%

Major Shareholders

  • How many BMRN shares are owned by institutional investors?
    315.6M BMRN shares are owned by institutional investors
  • How many BMRN shares are owned by insiders?
    2.5M BMRN shares are owned by insiders